The cost-effectiveness of transcatheter aortic valve implantation (TAVI) vs. surgical aortic
valve replacement (SAVR) has previously been reported across the spectrum of surgical mortality risk.
We present an updated analysis specific to the UK based on 4-year data from the Evolut Low Risk Trial, which showed a maintained numerical survival benefit with TAVI.
